Table 3 Demographic and disease characteristics in Norwegian RA patients starting non-naïve on b/tsDMARDs during 2010–2019
Ten year period | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | Mean | Missing Data Mean, Range | P value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The annual number of patients | |||||||||||||
All b/tsDMARDs starters | 832 | 887 | 875 | 857 | 852 | 946 | 1671 | 1342 | 1068 | 1475 | |||
Non-naïve starters, N (%) | 454 (55) | 463 (52) | 454 (52) | 471 (55) | 496 (58) | 579 (61) | 1271 (76) | 924 (69) | 660 (62) | 1066 (72) | 61% | ||
Demographics | |||||||||||||
Age (years) | 59 (14) | 57 (14) | 58 (14) | 57 (15) | 55 (14) | 578 (15) | 59 (14) | 58 (14) | 58 (15) | 59 (14) | 58 | 0.3%, 0–3% | < 0.001 |
Female | 75% | 79% | 78% | 75% | 790% | 79% | 71% | 76% | 75% | 74% | 76% | 0.0%, 0–0% | 0.002 |
BMI (kg/m2) | 26 (5.5) | 25 (4.6) | 26 (4.8) | 26 (5.1) | 26 (4.4) | 26 (5.1) | 26 (4.7) | 26 (4.7) | 26 (5.1) | 27 (5.0) | 26 | 19%, 6–65% | < 0.001 |
Education (years) | 12 (3.4) | 12 (3.9) | 12 (3.6) | 12 (3.8) | 13 (4.0) | 12 (3.7) | 12 (3.6) | 13 (3.8) | 13 (3.8) | 13 (3.7) | 13 | 29%, 18–59% | 0.019 |
Current Smokers | 27% | 26% | 22.0% | 17% | 14% | 19% | 18% | 16% | 12% | 14% | 18% | 28%, 18–58% | < 0.001 |
Disease Duration | 11 (10) | 11 (9.8) | 10 (8.6) | 13 (11) | 12 (9.7) | 13 (10) | 14 (11) | 13 (10) | 13 (11) | 13 (11) | 12 | 28%, 0–81% | 0.001 |
Enabled Workers | 54% | 51% | 52% | 63% | 57% | 54% | 60% | 59% | 59% | 58% | 57% | 26%, 15–54% | 0.106 |
Disease Activity | |||||||||||||
ESR (mm/h) | 32 (24) [25 (33)] | 28 (25) [21 (27)] | 28 (23) [21 (27)] | 30 (25) [21 (30)] | 27 (22) [21 (28)] | 24 (20) [19 (23)] | 22 (21) [16 (20)] | 22 (19) [15 (22)] | 24 (23) [16 (25)] | 20 (20) [13 (19)] | 26 | 23%, 15–41% | < 0.001 |
CRP (mg/L) | 21 (23) [12 (24)] | 18 (27) [8 (19)] | 16 (21) [7 (17)] | 17 (24) [7 (16)] | 16 (27) [6 (14)] | 14 (20) [5 (13)] | 12 (19) [5 (11)] | 12 (21) [5 (11)] | 14 (22) [5 (15)] | 11 (16) [5 (10)] | 15 | 19%, 11–37% | < 0.001 |
TJC28 (0–28) | 9.3 (6.8) [8 (10)] | 8.3 (7.0) [7 (9)] | 7.3 (6.6) [5 (9)] | 7.2 (6.4) [5 (8)] | 6.7 (5.9) [5 (8)] | 6.1 (6.3) [4 (8)] | 4.6 (5.5) [2 (7)] | 5.2 (5.5) [4 (7)] | 5.7 (5.7) [4 (8)] | 4.8 (5.8) [3 (7)] | 6.5 | 15%, 7–37% | < 0.001 |
SJC28 (0–28) | 7.3 (5.3) [6 (8)] | 6.2 (5.1) [5 (6)] | 5.7 (5.1) [4 (6)] | 5.2 (4.7) [4 (5)] | 4.4 (4.5) [3 (5)] | 4.0 (4.7) [3 (5)] | 3.1 (4.1) [2 (5)] | 3.6 (4) [3 (6)] | 3.7 (4.0) [3 (5)] | 2.9 (4.1) [1 (4)] | 4.6 | 15%, 7–37% | < 0.001 |
IGA (VAS, 0–100 mm) | 45 (21) | 40 (21) | 38 (20) | 40 (21) | 37 (19) | 37 (21) | 27 (21) | 32 (21) | 31 (19) | 28 (21) | 36 | 34%, 22–50% | < 0.001 |
DAS28 | 5.3 (1.4) | 5.0 (1.4) | 4.8 (1.4) | 4.7 (1.5) | 4.6 (1.4) | 4.3 (1.5) | 3.8 (1.6) | 4.0 (1.5) | 4.2 (1.6) | 3.8 (1.6) | 4.4 | 29%, 18–47% | < 0.001 |
Patient-Reported Outcome Measures | |||||||||||||
PGA (VAS, 0–100 mm) | 62 (22) | 58 (25) | 58 (25) | 56 (24) | 55 (24) | 51 (26) | 47 (28) | 49 (28) | 55 (27) | 49 (28) | 54 | 16%, 9–35% | < 0.001 |
Pain (VAS, 0–100 mm) | 57 (24) | 54 (26) | 54 (25) | 53 (24) | 51 (26) | 48 (26) | 45 (27) | 47 (28) | 52 (27) | 47 (28) | 51 | 23%, 13–52% | < 0.001 |
MHAQ (0–3) | 1.0 (0.6) | 0.9 (0.6) | 0.9 (0.5) | 0.8 (0.5) | 0.8 (0.6) | 0.6 (0.6) | 0.7 (0.6) | 0.7 (0.6) | 0.8 (0.6) | 0.7 (0.6) | 0.8 | 20%, 12–38% | < 0.001 |
Fatigue (VAS, 0–100 mm) | 58 (29) | 55 (28) | 57 (29) | 53 (28) | 56 (27) | 51 (29) | 48 (31) | 52 (31) | 54 (30) | 51 (31) | 54 | 38%, 15–56% | < 0.001 |
Morning Stiffness (hr) | 2.1 (1.7) | 1.9 (1.7) | 1.9 (1.7) | 1.7 (1.6) | 1.7 (1.7) | 1.5 (1.6) | 1.5 (1.6) | 1.6 (1.6) | 1.6 (1.7) | 1.4 (1.6) | 1.7 | 40%, 16–59% | < 0.001 |